Lonicera japonica protects Pelodiscus sinensis by inhibiting the biofilm formation of Aeromonas hydrophila

Huo, Li-Chao; Liu, Nai-Yu; Wang, Chao-Jie; Luo, Yi; Liu, Jing-Xia

doi:10.1007/s00253-023-12910-9

Cited by 1 publication

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, honeysuckle can reduce IL-6 or TNF-a release induced by the SARS-CoV-2, inhibiting cytokine storm and virus replication by blocking the binding of the SARS-CoV-2 spike protein to the ACE2 receptor to form a syncytium (35). Research has found that honeysuckle and its extract chlorogenic acid have antibacterial and immune-enhancing effects, and can inhibit the production of multidrug-resistant bacteria by inhibiting protein synthesis (36)(37)(38). Therefore, honeysuckle and its derivatives are expected to bring good therapeutic effects to co-infected patients.…”

Section: Discussionmentioning

confidence: 99%

Clinical and immunologic features of co-infection in COVID-19 patients, along with potential traditional Chinese medicine treatments

Zhang,

Gao

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

ObjectivesWith the increasing number of people worldwide infected with SARS-CoV-2, the likelihood of co-infection and/or comorbidities is rising. The impact of these co-infections on the patient’s immune system remains unclear. This study aims to investigate the immunological characteristics of secondary infections in hospitalized COVID-19 patients, and preliminarily predict potential therapeutic effects of traditional Chinese medicine and their derivatives for the treatment of co-infections.MethodsIn this retrospective cohort study, we included 131 hospitalized patients with laboratory-confirmed COVID-19, of whom there were 64 mild and 67 severe cases. We analyzed clinical characteristics and immunologic data, including circulating immune cell numbers, levels of inflammatory factors and viral load, comparing COVID-19 patients with and without co-infection.ResultsAmong 131 hospitalized COVID-19 patients, 41 (31.3%) were co-infection positive, with 33 (80.5%) having severe disease and 14 (34.1%) of them resulting in fatalities. Co-infected patients exhibited significantly higher severity and mortality rates compared to non-co-infected counterparts. Co-infected patients had significantly lower absolute counts of lymphocytes, total T lymphocytes, CD4+ T cells, CD8+ T cells and B lymphocytes, while levels of hs-CRP, PCT and IL-6 were significantly elevated compared to non-co-infected patients. Additionally, the viral load of co-infected patients was significantly higher than non-co-infected patients.ConclusionCo-infection emerges as a dangerous factor for COVID-19 patients, elevating the risk of severe pneumonia and mortality. Co-infection suppresses the host’s immune response by reducing the number of lymphocytes and increasing inflammation, thereby diminishing the antiviral and anti-infective effects of the immune system, which promotes the severity of the disease. Therefore, it is crucial to implement infection prevention measures to minimize the spread of co-infections among COVID-19 hospitalized patients. Additionally, changes in these biomarkers provide a theoretical basis for the effective treatment of co-infections with traditional Chinese medicine.

show abstract